# Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle

> **NCT00703378** · PHASE1,PHASE2 · COMPLETED · sponsor: **National University Hospital, Singapore** · enrollment: 33 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Docetaxel (Taxotere®)

## Key facts

- **NCT ID:** NCT00703378
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2011-02
- **Final completion:** 2012-02
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2012-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00703378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00703378, "Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00703378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*